IL155072A0 - Vaccine - Google Patents
VaccineInfo
- Publication number
- IL155072A0 IL155072A0 IL15507201A IL15507201A IL155072A0 IL 155072 A0 IL155072 A0 IL 155072A0 IL 15507201 A IL15507201 A IL 15507201A IL 15507201 A IL15507201 A IL 15507201A IL 155072 A0 IL155072 A0 IL 155072A0
- Authority
- IL
- Israel
- Prior art keywords
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0024089.5A GB0024089D0 (en) | 2000-10-02 | 2000-10-02 | Novel compounds |
PCT/EP2001/011326 WO2002028422A2 (en) | 2000-10-02 | 2001-10-01 | Split enveloped virus preparation for intranasal delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
IL155072A0 true IL155072A0 (en) | 2003-10-31 |
Family
ID=9900509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15507201A IL155072A0 (en) | 2000-10-02 | 2001-10-01 | Vaccine |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040022808A1 (xx) |
EP (1) | EP1324769A2 (xx) |
JP (1) | JP2004510744A (xx) |
KR (1) | KR20030031200A (xx) |
CN (1) | CN1477971A (xx) |
AU (1) | AU2002213984A1 (xx) |
BR (1) | BR0114393A (xx) |
CA (1) | CA2427842A1 (xx) |
CZ (1) | CZ2003931A3 (xx) |
GB (1) | GB0024089D0 (xx) |
HU (1) | HUP0302643A2 (xx) |
IL (1) | IL155072A0 (xx) |
NO (1) | NO20031483L (xx) |
PL (1) | PL362705A1 (xx) |
WO (1) | WO2002028422A2 (xx) |
ZA (1) | ZA200302522B (xx) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7270990B2 (en) | 2003-06-20 | 2007-09-18 | Microbix Biosystems, Inc. | Virus production |
DK1701738T3 (en) | 2003-12-17 | 2015-03-30 | Wyeth Llc | Process for preparing storage-stable RSV compositions |
CN1305526C (zh) * | 2003-12-29 | 2007-03-21 | 薛平 | 乙型脑炎病毒裂解疫苗及其制备方法 |
DE202005022108U1 (de) | 2004-03-09 | 2013-11-12 | Novartis Vaccines And Diagnostics, Inc. | Influenza-Virus-Impfstoffe |
CN101365480B (zh) * | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
PT2368572T (pt) | 2005-11-04 | 2020-06-16 | Seqirus Uk Ltd | Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular |
US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
CA2628424A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted influenza vaccines including cytokine-inducing agents |
KR20080089663A (ko) | 2006-01-27 | 2008-10-07 | 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
AU2007231027B2 (en) | 2006-03-24 | 2013-10-03 | Novartis Influenza Vaccines Marburg Gmbh | Storage of influenza vaccines without refrigeration |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
AU2007297178B2 (en) | 2006-09-11 | 2014-07-24 | Novartis Ag | Making influenza virus vaccines without using eggs |
US20110053248A1 (en) * | 2006-10-23 | 2011-03-03 | Medimmune, Llc | Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate |
WO2008068631A2 (en) | 2006-12-06 | 2008-06-12 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
NZ582595A (en) | 2007-06-27 | 2012-07-27 | Novartis Ag | Low-additive influenza vaccines |
US8497112B2 (en) * | 2007-08-28 | 2013-07-30 | Baxter International Inc. | Method for producing viral vaccines |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
JP5415449B2 (ja) | 2007-12-24 | 2014-02-12 | ノバルティス アーゲー | 吸着されたインフルエンザワクチンのためのアッセイ |
NZ587798A (en) | 2008-03-18 | 2013-06-28 | Novartis Ag | Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer |
CA2741961A1 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
WO2010079081A1 (en) | 2009-01-07 | 2010-07-15 | Glaxosmithkline Biologicals S.A. | Methods for recovering a virus or a viral antigen produced by cell culture |
EP2393922A1 (en) | 2009-02-06 | 2011-12-14 | GlaxoSmithKline Biologicals S.A. | Purification of virus or viral antigens by density gradient ultracentrifugation |
CN102307590A (zh) | 2009-02-10 | 2012-01-04 | 诺华有限公司 | 具有减少量的角鲨烯的流感疫苗 |
WO2010092477A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
CA2752039A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
DE102010018462A1 (de) | 2009-04-27 | 2011-04-07 | Novartis Ag | Impfstoffe zum Schutz gegen Influenza |
KR101800245B1 (ko) | 2009-05-21 | 2017-11-22 | 노파르티스 아게 | 비-내인성 pol i 프로모터를 사용하는 역 유전학 |
JP5716297B2 (ja) | 2009-06-25 | 2015-05-13 | Jnc株式会社 | クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法 |
CN102666860B (zh) | 2009-07-31 | 2015-06-17 | 诺华股份有限公司 | 反向遗传系统 |
US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
JP5774010B2 (ja) | 2009-09-25 | 2015-09-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | インフルエンザウイルスのための免疫拡散アッセイ |
PL2491117T3 (pl) | 2009-10-20 | 2014-05-30 | Novartis Ag | Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę |
WO2011138229A1 (en) | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
WO2011138682A2 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
JP5876036B2 (ja) | 2010-05-21 | 2016-03-02 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
PL2575873T3 (pl) | 2010-06-01 | 2016-06-30 | Novartis Ag | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
HUE051711T2 (hu) | 2010-06-01 | 2021-03-29 | Seqirus Uk Ltd | Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül |
WO2011154976A2 (en) | 2010-06-08 | 2011-12-15 | Panacea Biotec Limited | Improved influenza vaccine |
ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
US20140248320A1 (en) | 2011-10-20 | 2014-09-04 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
EP2820126B1 (en) | 2012-03-02 | 2017-05-17 | Seqirus UK Limited | Influenza virus reassortment |
EP2822585B1 (en) | 2012-03-06 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Improved vaccination against influenza |
JP2015526062A (ja) | 2012-06-04 | 2015-09-10 | ノバルティス アーゲー | 改善された安全性試験 |
KR102435054B1 (ko) * | 2012-08-01 | 2022-08-22 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
BR112015012380A2 (pt) | 2012-12-03 | 2017-09-12 | Novartis Ag | vírus influenza recombinante |
WO2014108515A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
AU2014229255B2 (en) | 2013-03-13 | 2018-12-13 | Novartis Ag | Influenza B virus reassortment |
JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
EP3004332A2 (en) | 2013-06-06 | 2016-04-13 | Novartis AG | Influenza virus reassortment |
JP6851827B2 (ja) * | 2013-08-30 | 2021-03-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 細胞培養中でのウイルスの大規模製造 |
KR20160068972A (ko) | 2013-11-15 | 2016-06-15 | 노파르티스 아게 | 잔여 세포 배양 불순물의 제거 |
WO2016008039A1 (en) | 2014-07-14 | 2016-01-21 | Novicol International Holding Inc. | Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof |
FR3025107B1 (fr) | 2014-08-29 | 2018-10-05 | Calixar | Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations |
BE1023903B1 (fr) | 2014-12-16 | 2017-09-08 | Glaxosmithkline Biologicals Sa | Nouveau procédé |
WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
WO2017005880A1 (en) | 2015-07-07 | 2017-01-12 | Seqirus UK Limited | Influenza potency assays |
CN107085095A (zh) * | 2017-03-02 | 2017-08-22 | 江苏华冠生物技术股份有限公司 | 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法 |
MX2021010194A (es) | 2019-02-25 | 2022-01-24 | Seqirus Uk Ltd | Vacunas contra la influenza multivalentes adyuvantadas. |
KR20220098370A (ko) | 2019-11-07 | 2022-07-12 | 세퀴러스 유케이 리미티드 | 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법 |
MX2022006005A (es) | 2019-11-18 | 2022-10-27 | Seqirus Pty Ltd | Metodo para producir virus de la influenza reagrupados. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4005528C2 (de) * | 1990-02-22 | 1998-01-15 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
EP1878424A3 (en) * | 1999-09-24 | 2008-04-09 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
-
2000
- 2000-10-02 GB GBGB0024089.5A patent/GB0024089D0/en not_active Ceased
-
2001
- 2001-10-01 CA CA002427842A patent/CA2427842A1/en not_active Abandoned
- 2001-10-01 AU AU2002213984A patent/AU2002213984A1/en not_active Abandoned
- 2001-10-01 CN CNA018198074A patent/CN1477971A/zh active Pending
- 2001-10-01 IL IL15507201A patent/IL155072A0/xx unknown
- 2001-10-01 WO PCT/EP2001/011326 patent/WO2002028422A2/en not_active Application Discontinuation
- 2001-10-01 EP EP01982385A patent/EP1324769A2/en not_active Withdrawn
- 2001-10-01 PL PL01362705A patent/PL362705A1/xx unknown
- 2001-10-01 BR BR0114393-0A patent/BR0114393A/pt not_active Application Discontinuation
- 2001-10-01 JP JP2002532246A patent/JP2004510744A/ja active Pending
- 2001-10-01 HU HU0302643A patent/HUP0302643A2/hu unknown
- 2001-10-01 US US10/381,354 patent/US20040022808A1/en not_active Abandoned
- 2001-10-01 CZ CZ2003931A patent/CZ2003931A3/cs unknown
- 2001-10-01 KR KR10-2003-7004719A patent/KR20030031200A/ko not_active Application Discontinuation
-
2003
- 2003-03-31 ZA ZA200302522A patent/ZA200302522B/en unknown
- 2003-04-01 NO NO20031483A patent/NO20031483L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0302643A2 (hu) | 2003-11-28 |
ZA200302522B (en) | 2004-06-30 |
PL362705A1 (en) | 2004-11-02 |
CN1477971A (zh) | 2004-02-25 |
KR20030031200A (ko) | 2003-04-18 |
AU2002213984A1 (en) | 2002-04-15 |
BR0114393A (pt) | 2003-08-26 |
NO20031483L (no) | 2003-05-28 |
WO2002028422A2 (en) | 2002-04-11 |
CZ2003931A3 (cs) | 2003-10-15 |
WO2002028422A3 (en) | 2002-08-29 |
GB0024089D0 (en) | 2000-11-15 |
NO20031483D0 (no) | 2003-04-01 |
CA2427842A1 (en) | 2002-04-11 |
JP2004510744A (ja) | 2004-04-08 |
EP1324769A2 (en) | 2003-07-09 |
US20040022808A1 (en) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0020953D0 (en) | Vaccine | |
HUP0301043A3 (en) | Vaccine | |
IL155072A0 (en) | Vaccine | |
IL155282A0 (en) | Vaccines | |
AU8189501A (en) | Vaccine composition | |
HUP0302117A3 (en) | Vaccine composition | |
GB0020089D0 (en) | Vaccine Composition | |
AU1591402A (en) | Vaccine | |
GB0130215D0 (en) | Vaccine | |
GB0407935D0 (en) | Vaccine | |
GB0024200D0 (en) | Component vaccine | |
EP1423141A4 (en) | VACCINE | |
GB0121171D0 (en) | Vaccine | |
GB0014288D0 (en) | Vaccine | |
GB0014845D0 (en) | Vaccine | |
GB0026334D0 (en) | Vaccine | |
GB0025694D0 (en) | Vaccine | |
GB0003082D0 (en) | Vaccine | |
GB0015722D0 (en) | Vaccine | |
GB0006693D0 (en) | Vaccine | |
GB0004533D0 (en) | Vaccines | |
GB0027433D0 (en) | Vaccine component | |
GB0015935D0 (en) | Vaccine | |
GB0018602D0 (en) | Vaccine | |
GB0025575D0 (en) | Vaccine |